Comparative Pharmacology
Head-to-head clinical analysis: CORT DOME versus POHERDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORT DOME versus POHERDY.
CORT-DOME vs POHERDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses, and inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Hydrocortisone (Cort-Dome) typical adult dose: 100 mg intravenously or intramuscularly as a loading dose, followed by 50-100 mg intravenously every 6 hours for stress dosing; for replacement therapy: oral 20-30 mg daily in divided doses. Topical: apply sparingly to affected area 1-4 times daily.
POHERDY: No approved drug. No dosing available.
None Documented
None Documented
Plasma half-life is approximately 1-2 hours; biological half-life (duration of adrenal suppression) is 18-36 hours.
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 40-60% of elimination; less than 5% excreted unchanged in urine; biliary/fecal elimination is minor (<5%).
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid